Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALEVE vs LINACLOTIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (c GMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Irritable bowel syndrome with constipation (IBS-C),Chronic idiopathic constipation (CIC)
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
145 mcg orally once daily, at least 30 minutes before the first meal of the day.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Approximately 9–10 hours (terminal half-life in plasma), supporting once-daily dosing.
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Minimally metabolized; primarily degraded by intestinal peptidases. Not a substrate for CYP450 enzymes.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Primarily fecal as intact peptide (95%); renal excretion of absorbed drug is minimal (<5%).
>99% bound to albumin; saturable at high concentrations.
Approximately 94% bound to plasma proteins (primarily albumin).
0.16 L/kg; indicates distribution primarily in extracellular fluid.
~5.2 L/kg (large Vd indicating extensive tissue distribution).
Oral: ~95%; immediate-release formulation.
Oral: ~0.1% (extremely low due to extensive degradation in GI tract and first-pass metabolism).
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease on dialysis.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C).
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Not approved for use in pediatric patients; safety and efficacy not established.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
No specific dose adjustment; caution advised due to potential increased sensitivity or gastrointestinal effects, but no pharmacokinetic differences observed in elderly vs younger adults.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
No boxed warning.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Not recommended in pediatric patients; avoid use in patients with known or suspected mechanical gastrointestinal obstruction.,May cause diarrhea, which can be severe; instruct patients to discontinue if severe diarrhea occurs.,Use caution in patients with inflammatory bowel disease (Crohn's, ulcerative colitis) or a history of colonic obstruction.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Known or suspected mechanical gastrointestinal obstruction.,History of a serious hypersensitivity reaction to linaclotide or any component of the formulation.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
Food reduces the efficacy of linaclotide; administer at least 30 minutes before a meal. Avoid taking with high-fat meals as they may delay gastric emptying and reduce drug effect. No specific dietary restrictions but maintaining adequate hydration is recommended due to possible diarrhea.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low due to negligible systemic exposure.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
Linaclotide is minimally absorbed systemically; its active metabolite is not measurable in plasma. No data on presence in human milk. M/P ratio unknown; likely low risk due to poor oral bioavailability and large molecular size.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
No dose adjustment needed; pharmacokinetic changes in pregnancy do not affect systemic exposure due to negligible absorption.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
Linaclotide is a guanylate cyclase-C agonist approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Onset of action can occur within 24 hours but maximal effect may take 1-2 weeks. Contraindicated in pediatric patients under 6 years due to risk of severe diarrhea. Avoid use in patients with mechanical gastrointestinal obstruction. Monitor for diarrhea, which may require dose reduction or discontinuation. Capsules should be swallowed whole; do not crush or chew. For patients with difficulty swallowing, capsules may be opened and sprinkled on applesauce or mixed in water for immediate consumption. Renal or hepatic impairment does not require dose adjustment. Linaclotide is not systemically absorbed (active locally).
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
Take linaclotide on an empty stomach, at least 30 minutes before the first meal of the day.,Swallow capsules whole; do not crush, chew, or break. If needed, open capsule and mix contents with applesauce or water and take immediately.,Do not take within 1 hour of eating or if you have a bowel obstruction.,Common side effects include diarrhea, which may be severe. Stop the medication and contact your doctor if you experience persistent or severe diarrhea.,Do not use in children under 6 years old.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALEVE vs LINACLOTIDE, answered by our medical review team.
ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. LINACLOTIDE is a Guanylate Cyclase-C Agonist that works by Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (c GMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALEVE and LINACLOTIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. The standard adult dose of LINACLOTIDE is: 145 mcg orally once daily, at least 30 minutes before the first meal of the day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALEVE and LINACLOTIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. LINACLOTIDE is classified as Category C. Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.